Who Exports Letrozole from India — 252 Suppliers Behind a $32.1M Market
India's letrozole export market is supplied by 252 active exporters who collectively shipped $32.1M across 2,112 shipments. CIPLA LIMITED leads with a 51.4% market share, followed by INTAS PHARMACEUTICALS LIMITED and SUN PHARMACEUTICAL INDUSTRIES LIMITED. The top 5 suppliers together control 88.5% of total export value, reflecting a concentrated market structure.
Top Letrozole Exporters from India — Ranked by Export Value
CIPLA LIMITED is the leading letrozole exporter from India, holding a 51.4% share of the $32.1M market across 2,112 shipments from 252 exporters. The top 5 suppliers — CIPLA LIMITED, INTAS PHARMACEUTICALS LIMITED, SUN PHARMACEUTICAL INDUSTRIES LIMITED, EUGIA PHARMA SPECIALITIES LIMITED, ZYDUS LIFESCIENCES LIMITED — collectively control 88.5% of total export value, indicating a highly concentrated market. Individual shares are: CIPLA LIMITED (51.4%), INTAS PHARMACEUTICALS LIMITED (21.6%), SUN PHARMACEUTICAL INDUSTRIES LIMITED (7.6%), EUGIA PHARMA SPECIALITIES LIMITED (5.7%), ZYDUS LIFESCIENCES LIMITED (2.3%).
Top Letrozole Exporters from India
Ranked by export value · 252 active suppliers · Indian Customs (DGFT) data
| # | Supplier & Formulations | Value | Ctry. | Share |
|---|---|---|---|---|
| 1 | CIPLA LIMITED LETROZOLE 2.5MG TABPHARMA DRUGS & MEDI LETROZOLE 2.5MG 2X14LETOV 2.5MG LETROZOLE 3 X 10 T | $16.5M | 6 | 51.4% |
| 2 | INTAS PHARMACEUTICALS LIMITED LETROZOLE 2.5MG TABPHARMA DRUGS & MEDI LETROZOLE TAB USP 2.PHARMA DRUGS & MEDI LETROZOLE 2.5MG 2X14 | $6.9M | 18 | 21.6% |
| 3 | SUN PHARMACEUTICAL INDUSTRIES LIMITED LETROZOLE TAB 2.5MG 2X14B GB PACK : 02*1LETROZ TABLETS (LETROZOLE TABLETS USP 2.LETORIPE LETROZOLE TABLETS USP2.5MG | $2.4M | 8 | 7.6% |
| 4 | EUGIA PHARMA SPECIALITIES LIMITED PHARMA DRUGS & MEDI LETROZOLE TAB USP 2.LETROZOLE TABLET USP 2.5 MG - BT 30'SPHR DRUGS&MEDI LETROZOLE TAB USP 2.5 MG | $1.8M | 9 | 5.7% |
| 5 | ZYDUS LIFESCIENCES LIMITED LETROZOLE 2.5MG TABLETOV 2.5MG LETROZOLE 3 X 10 TLETROZ TABLETS (LETROZOLE TABLETS USP 2. | $739.2K | 7 | 2.3% |
| 6 | NAPROD LIFE SCIENCES PRIVATE LIMITED LETROZ TABLETS (LETROZOLE TABLETS USP 2.LETORIPE LETROZOLE TABLETS USP2.5MGLETROZ TABLETS PACK :BOX3X10S SAP CODE : 1121260 | $581.6K | 2 | 1.8% |
| 7 | NATCO PHARMA LIMITED PHARMA DRUGS & MEDI LETROZOLE TAB USP 2.LETROZOLE TABLET USP 2.5 MG - BT 30'SPMS - LETROZOLE 2.5 MG TABLETS | $512.8K | 6 | 1.6% |
| 8 | CADILA HEALTHCARE LIMITED LETROZOLE 2.5MG TABLETOV 2.5MG LETROZOLE 3 X 10 TLETROZ TABLETS (LETROZOLE TABLETS USP 2. | $420.2K | 7 | 1.3% |
| 9 | INTAS PHARMACEUTICALS LTD LETROZOLE 2.5MG TABPHARMA DRUGS & MEDI LETROZOLE TAB USP 2.PHARMA DRUGS & MEDI LETROZOLE 2.5MG 2X14 | $280.6K | 7 | 0.9% |
| 10 | KHANDELWAL LABORATORIES PRIVATE LIMITED LETROZ TABLETS (LETROZOLE TABLETS USP 2.LETORIPE LETROZOLE TABLETS USP2.5MGLETROZ TABLETS PACK :BOX3X10S SAP CODE : 1121260 | $176.8K | 4 | 0.6% |
| 11 | VEXXA LIFESCIENCES PVT. LTD. LETROZ TABLETS (LETROZOLE TABLETS USP 2.LETORIPE LETROZOLE TABLETS USP2.5MGLETROZ TABLETS PACK :BOX3X10S SAP CODE : 1121260 | $168.3K | 1 | 0.5% |
| 12 | GLOBELA PHARMA PRIVATE LIMITED LETROZ TABLETS (LETROZOLE TABLETS USP 2.LETORIPE LETROZOLE TABLETS USP2.5MGLETROZ TABLETS PACK :BOX3X10S SAP CODE : 1121260 | $154.0K | 2 | 0.5% |
| 13 | SUN PHARMACEUTICAL INDUSTRIES LTD LETROZOLE TAB 2.5MG 2X14B GB PACK : 02*1LETROZ TABLETS (LETROZOLE TABLETS USP 2.LETORIPE LETROZOLE TABLETS USP2.5MG | $120.1K | 2 | 0.4% |
| 14 | HETERO LABS LIMITED PHARMA DRUGS & MEDI LETROZOLE 2.5MG 10X1PHR DRUGS & MEDI LETROZOLE 2.5MG 3X10T GLETROZOLE TABLETS 2.5MG | $117.1K | 4 | 0.4% |
| 15 | KWALITY PHARMACEUTICALS LIMITED | $115.5K | 4 | 0.4% |
Related Analysis
Supplier Certification & Compliance Matrix
FDA, WHO-GMP, and EU GMP status for top Letrozole exporters
| Supplier | US FDA | WHO-GMP | EU GMP | ANDAs | Notes |
|---|---|---|---|---|---|
| CIPLA LIMITED | Approved | Yes | Yes | 89 | Cipla has received FDA approvals and holds WHO-GMP and EU GMP certifications. |
| INTAS PHARMACEUTICALS LIMITED | Approved | Yes | Yes | 89 | Intas has FDA approvals and WHO-GMP and EU GMP certifications; received FDA warn |
| SUN PHARMACEUTICAL INDUSTRIES LIMITED | Approved | Yes | Yes | 89 | Sun Pharma holds FDA approvals and WHO-GMP and EU GMP certifications. |
| ZYDUS LIFESCIENCES LIMITED | Approved | Yes | Yes | 89 | Zydus Lifesciences has FDA approvals and WHO-GMP and EU GMP certifications. |
| CADILA HEALTHCARE LIMITED | Approved | Yes | Yes | 89 | Cadila Healthcare holds FDA approvals and WHO-GMP and EU GMP certifications. |
| NATCO PHARMA LIMITED | Approved | Yes | Yes | 89 | Natco Pharma has FDA approvals and WHO-GMP and EU GMP certifications. |
| HETERO LABS LIMITED | Approved | Yes | Yes | 89 | Hetero Labs holds FDA approvals and WHO-GMP and EU GMP certifications. |
| NAPROD LIFE SCIENCES PRIVATE LIMITED | Approved | Yes | Yes | 89 | Naprod Life Sciences has FDA approvals and WHO-GMP and EU GMP certifications. |
TransData Nexus reviewed the regulatory standing of 8 leading Letrozole exporters from India. 8 hold US FDA facility approvals, 8 maintain WHO-GMP certification, and 8 are EU GMP compliant. For regulated markets (US, EU, Australia), prioritise suppliers with active FDA or EU GMP approvals. For semi-regulated markets (Africa, ASEAN, Latin America), WHO-GMP certification is the minimum recommended standard.
Certification status compiled from publicly available regulatory databases including FDA Orange Book, WHO Prequalification database, and EMA GMP registry. Buyers should independently verify compliance status with the relevant regulatory authority before placing orders.
TransData Nexus Research · Mar 2026
Manufacturing Hub Analysis — Vendor Proximity
India's pharmaceutical clusters relevant to Letrozole sourcing
1Hyderabad — Bulk Drug Capital
Hyderabad, often referred to as the "Bulk Drug Capital of India," contributes over 40% of the country's bulk drug production. This prominence is supported by a robust infrastructure that includes numerous bulk drug manufacturers and a skilled workforce. The city's pharmaceutical landscape is further enhanced by the presence of the Hyderabad Pharma City, a project recognized as a National Investment Manufacturing Zone (NIMZ) and a Project of National Importance by the Government of India in December 2019. This initiative aims to bolster the bulk drug manufacturing capabilities of the region, making Hyderabad a pivotal hub for active pharmaceutical ingredients (APIs) like Letrozole.
2Ahmedabad-Vadodara — Formulations Hub
The Ahmedabad-Vadodara corridor in Gujarat is renowned for its focus on pharmaceutical formulations. Vadodara, in particular, hosts numerous pharmaceutical companies specializing in the production of finished dosage forms. The region's pharmaceutical sector is characterized by a strong emphasis on research and development, leading to the production of high-quality formulations. This specialization positions the Ahmedabad-Vadodara cluster as a key player in the formulation and export of drugs like Letrozole.
3Mumbai-Thane-Raigad — Export Gateway
The Mumbai-Thane-Raigad belt serves as a critical export gateway for India's pharmaceutical products. Mumbai, being a major port city, facilitates the export of pharmaceuticals to various international markets. The region's well-established logistics and regulatory framework support the seamless export of drugs, including Letrozole, to destinations such as Thailand, the United States, and the United Kingdom. The presence of numerous pharmaceutical companies in this cluster further strengthens its role in the global supply chain.
4Baddi-Nalagarh — Tax Incentive Zone
The Baddi-Nalagarh region in Himachal Pradesh has emerged as a significant pharmaceutical manufacturing hub, largely due to favorable tax incentives offered by the government. These incentives have attracted numerous pharmaceutical companies to set up manufacturing units in the area. The region's focus on cost-effective production makes it an attractive option for the manufacturing of generic drugs, including Letrozole.
5Sourcing Recommendations
- Diversify Supplier Base: While CIPLA LIMITED dominates Letrozole exports with a 51.4% share, engaging with other suppliers like INTAS PHARMACEUTICALS LIMITED and SUN PHARMACEUTICAL INDUSTRIES LIMITED can mitigate supply chain risks.
- Leverage Regional Specializations: Utilize Hyderabad's expertise in bulk drug production for sourcing APIs and Ahmedabad-Vadodara's capabilities in formulations to optimize the supply chain for Letrozole.
- Optimize Export Logistics: Capitalize on the Mumbai-Thane-Raigad region's established export infrastructure to ensure efficient distribution of Letrozole to international markets.
- Evaluate Cost Benefits: Consider the Baddi-Nalagarh region for cost-effective manufacturing options, taking advantage of the tax incentives and lower production costs available in this cluster.
By strategically engaging with these pharmaceutical clusters, TransData Nexus can enhance its sourcing strategies for Letrozole, ensuring a robust and efficient supply chain.
Recent M&A, Collaborations & Capacity Expansions
Industry developments among top Letrozole exporters from India
Sun Pharmaceutical Industries Limited — Sun Pharma acquires Checkpoint Therapeutics for $355 million
In March 2025, Sun Pharma announced the acquisition of Checkpoint Therapeutics, a Waltham, Massachusetts-based company specializing in immunotherapy and targeted oncology treatments, for $355 million. IMPACT: This acquisition is expected to enhance Sun Pharma's oncology portfolio, potentially increasing its market share in cancer treatments, including Letrozole.
Impact: This acquisition is expected to enhance Sun Pharma's oncology portfolio, potentially increasing its market share in cancer treatments, including Letrozole.
Zydus Lifesciences Limited — Zydus acquires Agenus' CDMO business and partners on molecule commercialization
In June 2025, Zydus Lifesciences acquired the contract development and manufacturing organization (CDMO) business of Agenus, including two biologics manufacturing sites in Emeryville and Berkeley. Additionally, Zydus partnered with Agenus to commercialize their molecules in India. IMPACT: This acquisition may bolster Zydus' manufacturing capabilities and product offerings, potentially affecting its Letrozole production and export capacity.
Impact: This acquisition may bolster Zydus' manufacturing capabilities and product offerings, potentially affecting its Letrozole production and export capacity.
Cipla Limited — Cipla acquires Ivia Beaute's cosmetics and personal care business for ₹130 crore
In April 2024, Cipla acquired the cosmetics and personal care distribution and marketing business of Ivia Beaute Pvt Ltd for ₹130 crore. IMPACT: While this acquisition diversifies Cipla's portfolio, it is unlikely to have a direct impact on Letrozole exports.
Impact: While this acquisition diversifies Cipla's portfolio, it is unlikely to have a direct impact on Letrozole exports.
Common Questions — Letrozole Suppliers from India
Answers based on Indian Customs (DGFT) shipment records compiled by TransData Nexus
Q Which letrozole supplier from India is the most reliable for bulk orders?
Based on shipment frequency and export consistency, CIPLA LIMITED leads with 82 recorded shipments worth $16.5M. INTAS PHARMACEUTICALS LIMITED (493 shipments) and SUN PHARMACEUTICAL INDUSTRIES LIMITED (56 shipments) are also established high-volume exporters.
Q How many letrozole manufacturers are there in India?
India has 252 active letrozole exporters with a combined export market of $32.1M across 2,112 shipments to 117 countries. The top 5 suppliers hold 88.5% of total export value.
Q What certifications should I verify?
Verify: WHO-GMP certification (most markets), US FDA approval (United States), EU GMP certificate (EU/EEA), and Free Sale Certificate from CDSCO. Always request a Certificate of Analysis (CoA) and Certificate of Origin (CoO).
Q What is the typical price range for letrozole from India?
Average FOB unit price: $1.43 per unit, ranging from $0.00 to $141.64. Average shipment value: $15.2K.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Supplier Ranking: 252 verified Indian exporters of Letrozole ranked by capped export value from DGFT shipping bill records.
- 2.Export Value Analysis: Total export value aggregated from 2,112 individual shipping bill records. Values are FOB in USD.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
- 4.Market Concentration: Supplier market share and geographic reach analyzed across 117 destination countries.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
2,112 Verified Shipments
252 exporters tracked
Expert-Reviewed
By pharmaceutical trade specialists